Insights

More Articles Back to Article

UK's NHS, Novartis partner to accelerate review of inclisiran

The UK's National Health Service and Novartis have partnered to advance the accelerated review by the National Institute for Health and Care Excellence for its cholesterol-lowering drug inclisiran in order to make it available to the public by 2021. The collaboration will also involve the launch of a clinical trial in the UK to determine which patients are at risk for heart disease and who have not responded well to conventional treatments based on NHS data. PMLive (UK) (1/14)

立即阅读整篇文章。

文章仅仅是 DIA 会员的专享福利之一。了解详情并立即加入,不再错过任何文章!